Navigation Links
Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
Date:4/10/2013

April 10, 2013, New York, NY A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week's American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

"With new immunotherapy agents available to help patients with melanoma, researchers are developing prognostic biomarkers to determine who will benefit most to fully realize the potential of these treatments," explained Jedd D. Wolchok, PhD, MD, director of Ludwig's Collaborative Laboratory at Memorial Sloan-Kettering Cancer Center during his presentations at AACR. "By identifying targeted combinations of agents, the immune response can be improved in certain patients with melanoma, the most dangerous form of skin cancer."

Developments in immunotherapeutic treatment of ovarian cancer was highlighted in a "Meet the Expert" session with George Coukos, PhD, MD, director of the Ludwig Center for Cancer Research of the University of Lausanne. His presentation educated on current progress and future prospects in vaccine and adoptive T-cell therapy development, as well as immunomodulatory therapy tools available for immediate clinical testing. "Ovarian cancer remains a very important therapeutic challenge," commented Dr. Coukos. "With no drugs approved in two decades in the U.S. and no therapeutic targets emerging from deep sequencing analyses, immunotherapy could offer a promising new approach."

Dr. Geoffrey Greene's team at the Ludwig Center at the University of Chicago analyzed epigenetic regulators called microRNAs little pieces of ribonucleic acid that are present in all the cells in the body to better understand treatment challenges of metastasis and chemotherapy resistance in patients with triple negative breast cancer.

"Our research used a novel human tumor xenograft model to better understand the fundamental mechanisms of these tumors," said lead author Huiping Liu, Research Associate, Ben May Department and the Ludwig Center, University of Chicago. "We know that proteins turn genes on and off but so do microRNAs. Our team discovered a small yet influential microRNA known as 30c. When it is present in cells it inhibits metastasis and improves a patient's response to chemotherapy treatment. Our findings may provide a potential new treatment target for this difficult to treat cancer."

From Dr. Bing Ren's laboratory of gene regulation at the Ludwig Institute for Cancer Research in San Diego, post-doctoral fellow Gary Hon, PhD described how adult tissues retain an epigenetic memory of their past development. Further, Dr. Ren shared research related to long-range control of gene expression in mammalian cells during an educational session.


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related biology news :

1. Ludwig cancer researchers honored among first class of fellows in AACR Academy
2. Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
3. Report presents designs for study of cancer risks near US nuclear facilities
4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
5. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
6. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
7. Crop Science Society of America presents 2012 class of fellows
8. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
9. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
10. July meeting presents animal and dairy science
11. International Life Sciences Conferences Address Advancements in High-Content Analysis, Sample Preparation, Clinical Trial Supply and Protein and Antibody Engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/6/2019)... ... June 05, 2019 , ... ... opening of a new network station and service center in Mexico City, Mexico. ... in the world — with more than $1.75 billion in pharmaceutical exports since ...
(Date:6/4/2019)... JOSE, Calif. (PRWEB) , ... June 04, 2019 ... ... analytical technologies, today announced the appointment of Susan Murphy as the new President ... Coulter Life Sciences?owned by Molecular Devices’ parent company, Danaher Corporation. , Since joining ...
(Date:6/4/2019)... ... 04, 2019 , ... Lajollacooks4u is delighted to announce it has been named ... excellence, is given only to businesses that have achieved consistently outstanding traveler reviews on ... , To qualify for the Certificate of Excellence –- an award that only ...
Breaking Biology News(10 mins):
(Date:7/17/2019)... ... 2019 , ... Quidel is the market leader in point-of-care ... and Siemens Healthineers and Response Biomedical also are among the top companies. The ... (POC) Diagnostics . , Quidel is a market leader in rapid immunoassays and ...
(Date:7/9/2019)... ... 08, 2019 , ... Balluff has been named a 2019 ... 2019 Innovative Product of the Year which highlights cutting-edge advancements and achievements that ... Expo & Conference 2019, held this week in San Jose, California. , ...
(Date:6/18/2019)... SOMERSET, N.J. (PRWEB) , ... June 17, 2019 ... ... today announced that they have entered into an agreement for production and manufacturing ... IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 ...
(Date:6/11/2019)... , ... June 10, 2019 , ... ... its distribution network with the appointment of Biofeedback Tech Ltd as ... systems are an essential part of many therapeutic treatments and clinical assessment protocols ...
Breaking Biology Technology: